Familial Mediterranean fever (FMF) is an inherited inflammatory disease occurring mainly in Mediterranean and Middle Eastern populations. FMF is caused by mutations in the MEFV gene that encodes pyrin/marenostrin. Here, we report a Japanese female FMF patient with heterozygosity for the compound pyrin E148Q/M694I showing recurrent fever, serositis or delay in skin wound healing. Her father and elder sister were heterozygous for pyrin variant M694I alone and sometimes suffered from mild fever or delay in wound healing, but her mother was heterozygous for pyrin variant E148Q alone and had no symptoms. This suggested that the inheritance of FMF occurred not only in an autosomal recessive manner but also in an autosomal dominant manner in this Japanese family, and the severity of the disease differed among the family members in relation to the mutation. In the treatment of FMF, colchicine, reserpine or prazosin hydrochloride have been reported to prevent the attacks, but, in our patient such drugs were ineffective or caused side effects, and only the anti-allergic drug azelastine was of benefit in relieving the attacks. (Internal Medicine 44: 261-265, 2005) 
Introduction
Familial Mediterranean fever (FMF) is an inherited disease characterized by periodic fever, polyserositis and erysipelas-like skin lesions (1, 2) . FMF has been predominantly found among people of non-Ashkenazi Jewish, Arab, Armenian, and Turkish origin, and is quite rare in Japan. In the majority of cases the inheritance of FMF is commonly in an autosomal recessive manner, but a pseudodominant or dominant manner has been identified in a minority of cases (3, 4) . FMF is caused by mutations in the Mediterranean fever gene (MEFV) on chromosome 16p13.3 and approximately 30 mutations have been reported to date. The gene encodes pyrin/marenostrin and the protein predominantly expressed in the cytoplasm of mature neutrophils and monocytes, but its precise function remains unclear (2) . Reactive AA amyloidosis frequently occurrs in the patients with this disease and the prognosis is determined by the complication of AA amyloidosis (1, 2) . In Japan, although 20 cases with FMF have been reported to date, only a few cases were diagnosed by MEFV gene analysis (5) (6) (7) (8) .
Here we first present a FMF patient associated with heterozygosity for compound pyrin variant E148Q/M694I in Japan, and family members with heterozygosity for M694I alone suffered from less severe symptoms.
Case Report
A 34-year-old Japanese female repeatedly suffed from fever, chest and abdominal pain, arthralgia or delay in skin wound healing since the age of 20. The symptoms used to occur one or more times a month, and were especially severe during menstruation. She had been diagnosed as having an unidentified form of infection in several different hospitals and had taken anti-inflammatory drugs or antibiotics, which provided relief for a few days. At the age of 33 she became psychotic and attempted suicide with a large amount of tran- quilizers, and was admitted to a nearby hospital. In hospital she repeatedly had a fever with elevation of serum C-reactive protein (CRP) (max: 16.9 mg/dl), but examinations did not reveal the cause and subsequently she was referred to our university hospital. Her body temperature was 37.3°C, blood pressure 97/76 mmHg, and pulse rate 70 beats/min and regular. The heart and lungs were normal. Tenderness was observed in the lower abdomen and some pigmented scars from insect bites were present on the lower legs. She lacked eye symptoms, oral stomatitis ulcers, lymphadenopathy, or arthropathy. The laboratory examinations revealed only an elevation of CRP (5.44 mg/dl), erythrocyte sedimentation rate (23 mm/h) and serum amyloid A protein (144 g/ml; normal <8 g/ml), but other laboratory investigations did not disclose any specific abnormalities ( Table 1 ). All bacteriologic cultures of pharynx, blood, and urine were negative. Findings of cerebrospinal fluid and bone marrow aspiration were not informative. X-ray films and computed tomography of both chest and abdomen, Ga scintigraphy, and echocardiography revealed no abnormal findings. Thus, the extensive investigation failed to reveal such causes of her disorder as infections, autoimmune disorders including Béhçhet's disease, or malignancy. Considering that fever and serositis recurrently appeared and her father and elder sister also sometimes showed mild fever or delay in wound healing, the most likely diagnosis was familial Mediterranean fever (FMF), although her parents were not consanguineous. To perform a mutation search in the MEFV gene, after obtaining informed consent, we extracted genomic DNA from peripheral lymphocytes of the patient and her family members by the standard procedure. For PCR amplification of the gene we used the nine primer sets, and PCR amplification was performed as described in a previous report (9) . Direct sequencing for PCR products was carried out using an automatic DNA sequencer Model 4000L, LI-COR in both directions. Mutation search revealed a compound heterozygosity for pyrin E148Q/M694I mutation in the patient ( Fig. 1 ): these mutations have been reported previously (2) . Her father and elder sister were hetrozygous for pyrin variant M694I alone and her mother was heterozygous for pyrin E148Q alone, while her brother had no mutation in the gene (Fig. 2) . Although her serum amyloid A protein level was very high (144 g/ml; normal < 8 g/ml), gastric and duodenal mucosal biopsies did not show any deposits of amyloid and renal function was normal. Since colchicine has been established as effective in preventing attacks and subsequent development of amyloidosis (1, 2), 1mg daily was administered orally and her symptoms remitted for some time. However, one month later she suffered from severe abdominal pain and diarrhea due to side effects of the colchicine and the drug was discontinued. Reserpine (10) or prazosin hydrochloride (11) has been reported to be effective, but we could not give her either drug because of her psychosis and hypotension (systolic blood pressure <100 mmHg). Diclofenac sodium relieved her fever but not the pain, while pentazocine hydrochloride or buprenorphine hydrochloride was useful for pain relief but not for fever. Accordingly we needed to seek another treatment and focused on colchicine's characteristic function: inhibition of neutrophil chemotactic activity (12) . We searched for another drug having a similar function and found that azelastine, which is an anti-allergic drug, also inhibits neutrophil chemotaxis (13) . We have since been administering 4-6 mg of azelastine to her daily and her attacks of fever and polyserositis have decreased.
Discussion
We presented a severe FMF patient associated with heterozygosity for the compound pyrin variant E148Q/ M694I. Interestingly, two family members, who were heterozygous for pyrin M694I alone, also suffered from mild attacks of fever of unknown origin or delay in wound healing, while her mother with heterozygosity for E148Q alone was asymptomatic. It has been reported that FMF patients with several pyrin M694 variants often show a severe phenotype (2) , that the methionine residue at position 694 makes a crucial contribution to pyrin's function, and that a 50% complement of normal pyrin activity may not prevent FMF symptoms (3). Given these reports, it is not surprising that our FMF carriers associated with heterozygosity for pyrin variant M694I alone showed some FMF symptoms, and a pyrin variant M694I accompanied by variant E148Q in the patient could cause the definite FMF phenotype. Recently it has been documented that an H478Y variant alone in a Spanish kindred produced a severe FMF phenotype with amyloidosis (14) . Thus the inheritance of FMF sometimes shows an autosomal dominant or pseudodominant pattern (3, 4) , and we first confirmed the presence of pseudodominant inheritance in a Japanese family. The pattern of inheritance may depend on the location of the mutation in the MEFV gene.
On the other hand, the role of pyrin E148Q as a mutation in FMF has been controversial. It has been described that the allele frequency of pyrin E148Q in normal controls was relatively high, and some healthy individuals had a homozygous pyrin E148Q, thus pyrin E148Q has been considered to be a normal variant (15, 16) . However, it has also been reported that the allele frequency of pyrin E148Q is significantly higher among patients with AA amyloidosis and with unknown chronic fever, and it might produce FMF when associated with certain other MEFV mutations (17) . Taking this report and the relationship between phenotype and genotype in our family together, we speculate that heterozygosity for pyrin E148Q alone might not reach the necessary threshold to cause FMF, that heterozygosity for pyrin M694I alone might be slightly over the threshold, and that a compound heterozygosity for E148Q and M694I might be enough to go beyond the threshold and produce the definite FMF phenotype. The pyrin E148Q mutation itself might be insufficient to cause FMF, and some individuals even with homozygosity for pyrin E148Q might have no or very mild symptoms.
In treating attacks of FMF, colchicine has been established to be effective in preventing them and in secondarily occurring amyloidosis, but side effects such as abdominal symptoms or bone marrow suppression are often encountered. Reserpine (10) and prazosin hydrochloride (11) have also been reported to be useful and diclofenac sodium, pentazocine hydrochloride and buprenorphine hydrochloride have been used for pain relief and fever (2). Unfortunately the above drugs were either only partially effective in our patient or could not be used at all. Accordingly we focused on colchicine's characteristic function of inhibiting neutrophil chemotactic activity (12) and found that the anti-allergic drug azelastine also inhibits neutrophil chemotaxis (13) . Azelastine, like colchicine, successfully reduced the frequency and degree of the attacks in the present patient. It controls neutrophil function by inhibition of leukotriene B4 formation, arachidonic acid release and superoxide generation (13) . As in our case, when colchicine or other drugs cannot be tolerated because of side effects or contraindications in patients with FMF, azelastine should be considered.
In summary, we reported the first Japanese case of FMF identified to be associated with compound heterozygosity for pyrin variant E148Q/M694I. The FMF gene carriers with heterozygosity for pyrin variant M694I alone also experienced milder or slight symptoms. Accordingly it is possible that such mild cases might often be overlooked and we should consider the possibility of FMF in the differential diagnosis of recurrent fever or serositis of unknown origin. 
